Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Fumigant 93 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Peripheral Nervous System Diseases 1 Multiple Myeloma 1 Hodgkin Disease 1 Disseminated Intravascular Coagulation 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Age Problem 1

Interventions

Carboplatin 695 Pemetrexed 535 Cisplatin 484 Paclitaxel 431 pembrolizumab 409 Docetaxel 391 Gemcitabine 286 Erlotinib Hydrochloride 282 Radiotherapy 226 Bevacizumab 213 Nivolumab 212 osimertinib 152 durvalumab 143 Drug Therapy 140 Gefitinib 120 atezolizumab 117 Radiosurgery 112 Vinorelbine 98 Cetuximab 84 130-nm albumin-bound paclitaxel 83 Magnetic Resonance Spectroscopy 80 Taxes 71 Ipilimumab 70 Surgical Procedures, Operative 66 Albumin-Bound Paclitaxel 61 Afatinib 58 Specimen Handling 57 Cyclophosphamide 56 tislelizumab 54 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02504489 2022-09-10

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡